Disclosure: S. Müller, None; M. Jain, None; B. Sachdeva, None; P.N. Shah, None; F.G. Holz, Acucela (F), Allergan (F), Apellis (F), Bayer (F), Bioeq/Formycon (F), CenterVue (F), Ellex (F), Roche/Genentech (F), Geuder (F), Kanghong (F), NightStarx (F), Novartis (F), Optos (F), Zeiss (F); Acucela (C), Aerie (C), Allergan (C), Apellis (C), Bayer (C), Boehringer-Ingelheim (C), Ivericbio (C), Roche/Genentech (C), Geuder (C), Grayburg Vision (C), Ivericbio (C), LinBioscience (C), Kanghong (C), Novartis (C), Pixium Vision (C), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (C); R.P. Finger, Novartis (F), CentreVue (F), Heidelberg Engineering (F), Zeiss (F); Novartis (C), Bayer (C), Roche/Genentech (C), Ellex (C), Alimera (C), Allergan (C), Santhera (C), Inositec (C), Opthea (C); K. Murali, None; M.W.M. Wintergerst, ASKIN & CO GmbH (R), Bayer AG (R), Berlin-Chemie AG (R, F), CenterVue SpA (non-financial support), Carl Zeiss Meditec (non-financial support), D-Eye Srl (non-financial support), DigiSight Technologies (F, non-financial support), Eyenuk, Inc. (non-financial support), Eyepress Fachmedien GmbH (R), Glaucare GmbH (owner, C), Heine Optotechnik GmbH (C, R, F, non-financial support), Heidelberg Engineering (R, non-financial support), Novartis Pharma GmbH (R, non-financial support), Optos (non-financial support), Pro Generika e.V. (R), Science Consulting in Diabetes GmbH (R); T. Schultz, None